What is the recommended dosage of Robaxin (methocarbamol) for muscle relaxation and treatment of muscle spasms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Robaxin (Methocarbamol) for Muscle Spasms

The recommended initial dosage of Robaxin (methocarbamol) for adults is 1500 mg (three 500 mg tablets) four times daily or 1500 mg (two 750 mg tablets) four times daily for the first 48-72 hours of treatment, followed by a maintenance dose of 1000 mg (two 500 mg tablets) four times daily or 750 mg (one 750 mg tablet) every 4 hours or 1500 mg (two 750 mg tablets) three times daily. 1

Dosage Regimen

  • Initial therapy should provide 6 grams per day for the first 48-72 hours (for severe conditions, up to 8 grams per day may be administered) 1
  • After the initial treatment period, the dosage can usually be reduced to approximately 4 grams per day 1
  • The medication is available in two strengths:
    • 500 mg tablets: Initial dose of 3 tablets four times daily, maintenance dose of 2 tablets four times daily 1
    • 750 mg tablets: Initial dose of 2 tablets four times daily, maintenance dose of 1 tablet every 4 hours or 2 tablets three times daily 1

Clinical Efficacy

  • Methocarbamol has been shown to be effective in approximately 60% of patients with painful muscle spasm compared to 30% with placebo (p<0.01) 2
  • In a randomized controlled study of acute low back pain with muscle spasms, 44% of patients taking methocarbamol achieved complete pain relief compared to only 18% of those on placebo 3
  • The medication is well-established for the treatment of low back pain associated with myofascial components 3

Safety Considerations and Precautions

  • Methocarbamol should be held on the day of surgery according to the Mayo Clinic Proceedings 4
  • Common adverse effects include drowsiness, dizziness, and potential cardiovascular effects including bradycardia and hypotension 4
  • Methocarbamol elimination is significantly impaired in patients with liver and kidney disease, requiring dosage adjustments 4
  • The medication may interfere with the effects of pyridostigmine bromide and should not be used in patients with myasthenia gravis 4
  • Side effects are generally mild and occur at a rate similar to placebo in clinical trials 2

Important Warnings

  • Methocarbamol should not be combined with alcohol, as this interaction can lead to combined central nervous system depression due to interactive sedative-hypnotic properties, which can be potentially fatal 5
  • Caution should be exercised when using methocarbamol in elderly patients due to increased risk of adverse effects 6
  • The medication may cause drowsiness and impair the ability to drive or operate machinery 4

Alternative Options

  • For patients who cannot tolerate methocarbamol or have contraindications, cyclobenzaprine may be considered, though it has more pronounced anticholinergic effects 7
  • Baclofen (starting at 10 mg/day with weekly increases up to 30 mg/day) may be more appropriate for severe muscle cramps 7

Methocarbamol remains one of the most commonly prescribed muscle relaxants due to its relatively favorable side effect profile compared to other agents in this class 8. When prescribing, always consider the patient's renal and hepatic function, concomitant medications, and potential for sedation.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Methocarbamol and Cyclobenzaprine Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cyclobenzaprine Dosing and Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Centrally acting skeletal muscle relaxants and associated drugs.

Journal of pain and symptom management, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.